Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
100.71 (1y: +17%)
Market Cap 9.27 B P/E(ttm) 17.30
Enterprise Value 11.41 B P/B 3.40
LH- NYSE (USA)
Laboratory Corporation of America Holdings
  • Currently 5/5
Business Predictability Rank: 5-Star
Back Testing Results:
Average gain of all 5-Star stocks: 12.1% per year.
% of Stocks that are in still loss if held for 10yrs: 3%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$100.71
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry		 vs
history
Cash to Debt 0.176
LH's Cash to Debt is ranked lower than
81% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. LH: 0.176 )
LH' s 10-Year Cash to Debt Range
Min: 0.06   Max: 0.29
Current: 0.18
0.06
0.29
Equity to Asset -0.273
LH's Equity to Asset is ranked lower than
1111110% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. LH: -0.273 )
LH' s 10-Year Equity to Asset Range
Min: -0.29   Max: 0.15
Current: -0.27
-0.29
0.15
Interest Coverage 10.9
LH's Interest Coverage is ranked lower than
60% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. LH: 10.9 )
LH' s 10-Year Interest Coverage Range
Min: 4   Max: 28
Current: 10.9
4
28
F-Score: 6
Z-Score: 3.62
M-Score: -2.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 18.00
LH's Operating margin (%) is ranked higher than
79% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. LH: 18.00 )
LH' s 10-Year Operating margin (%) Range
Min: 8.8   Max: 19.9
Current: 18
8.8
19.9
Net-margin (%) 10.3
LH's Net-margin (%) is ranked higher than
77% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. LH: 10.3 )
LH' s 10-Year Net-margin (%) Range
Min: 3.9   Max: 12
Current: 10.3
3.9
12
ROE (%) 21.5
LH's ROE (%) is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. LH: 21.5 )
LH' s 10-Year ROE (%) Range
Min: 8.9   Max: 27.6
Current: 21.5
8.9
27.6
ROA (%) 8.6
LH's ROA (%) is ranked higher than
77% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. LH: 8.6 )
LH' s 10-Year ROA (%) Range
Min: 4.1   Max: 11.2
Current: 8.6
4.1
11.2
ROC (Joel Greenblatt) (%) 101.60
LH's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.00 vs. LH: 101.60 )
LH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.7   Max: 136.3
Current: 101.6
25.7
136.3
Revenue Growth (%) 7.9
LH's Revenue Growth (%) is ranked higher than
80% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. LH: 7.9 )
LH' s 10-Year Revenue Growth (%) Range
Min: -14.3   Max: 14.8
Current: 7.9
-14.3
14.8
EBITDA Growth (%) 5.5
LH's EBITDA Growth (%) is ranked higher than
83% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.85 vs. LH: 5.5 )
LH' s 10-Year EBITDA Growth (%) Range
Min: -4.3   Max: 14.3
Current: 5.5
-4.3
14.3
EPS Growth (%) 4.7
LH's EPS Growth (%) is ranked higher than
83% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.90 vs. LH: 4.7 )
LH' s 10-Year EPS Growth (%) Range
Min: 4.7   Max: 55.9
Current: 4.7
4.7
55.9
ยป LH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

LH Guru Trades in Q2 2012

Richard Pzena 75,986 sh (New)
Chuck Royce 85 sh (New)
Jeremy Grantham 951,208 sh (+600.92%)
Wallace Weitz 567,850 sh (+1.29%)
John Hussman 500,000 sh (unchged)
Westport Asset Management 150,000 sh (unchged)
Vanguard Health Care Fund 2,681,360 sh (unchged)
Ronald Muhlenkamp 51,895 sh (-0.11%)
Glenn Greenberg 842,251 sh (-5.58%)
Joel Greenblatt 20,851 sh (-6.28%)
Scott Black 6,897 sh (-22.3%)
Mark Hillman 2,690 sh (-51.88%)
Ray Dalio 13,516 sh (-64.68%)
Steven Cohen 2,282 sh (-85.68%)
» More
Q3 2012

LH Guru Trades in Q3 2012

Mario Gabelli 3,000 sh (New)
Steven Cohen 4,975 sh (+118.01%)
Jeremy Grantham 2,058,378 sh (+116.4%)
Joel Greenblatt 29,385 sh (+40.93%)
Chuck Royce 110 sh (+29.41%)
Ray Dalio 16,116 sh (+19.24%)
Wallace Weitz 574,850 sh (+1.23%)
Vanguard Health Care Fund 2,681,360 sh (unchged)
Westport Asset Management 150,000 sh (unchged)
Glenn Greenberg 838,559 sh (-0.44%)
Mark Hillman 2,649 sh (-1.52%)
Ronald Muhlenkamp 51,090 sh (-1.55%)
Richard Pzena 72,861 sh (-4.11%)
Scott Black 6,562 sh (-4.86%)
John Hussman 285,000 sh (-43%)
» More
Q4 2012

LH Guru Trades in Q4 2012

Chris Davis 554,820 sh (New)
Richard Pzena 808,992 sh (+1010.32%)
Ray Dalio 58,338 sh (+261.99%)
Joel Greenblatt 42,783 sh (+45.59%)
Mario Gabelli 4,000 sh (+33.33%)
Scott Black 8,352 sh (+27.28%)
Wallace Weitz 584,850 sh (+1.74%)
Jeremy Grantham 2,573,578 sh (unchged)
Westport Asset Management 150,000 sh (unchged)
Ronald Muhlenkamp Sold Out
Chuck Royce Sold Out
Glenn Greenberg Sold Out
Steven Cohen Sold Out
Mark Hillman 2,644 sh (-0.19%)
Vanguard Health Care Fund 2,581,360 sh (-3.73%)
John Hussman 184,000 sh (-35.44%)
» More
Q1 2013

LH Guru Trades in Q1 2013

Jim Simons 159,500 sh (New)
Charles Brandes 117,076 sh (New)
Chris Davis 4,160,386 sh (+649.86%)
Richard Pzena 2,306,707 sh (+185.13%)
Ray Dalio 72,898 sh (+24.96%)
Wallace Weitz 612,850 sh (+4.79%)
Westport Asset Management 150,000 sh (unchged)
Mario Gabelli 4,000 sh (unchged)
John Hussman Sold Out
Mark Hillman Sold Out
Vanguard Health Care Fund Sold Out
Jeremy Grantham 2,568,678 sh (-0.19%)
Scott Black 8,301 sh (-0.61%)
Joel Greenblatt 30,558 sh (-28.57%)
» More
» Details

Insider Trades

Latest Guru Trades with LH

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2013-03-31 Sold Out 0.59%$86.41 - $91.63 $ 100.7113%0
John Hussman 2013-03-31 Sold Out 0.42%$86.41 - $91.63 $ 100.7113%0
Charles Brandes 2013-03-31 New Buy0.12%$86.41 - $91.63 $ 100.7113%117076
Wallace Weitz 2013-03-31 Add 4.79%0.11%$86.41 - $91.63 $ 100.7113%612850
Joel Greenblatt 2013-03-31 Reduce -28.57%0.06%$86.41 - $91.63 $ 100.7113%30558
Ray Dalio 2013-03-31 Add 24.96%0.01%$86.41 - $91.63 $ 100.7113%72898
Glenn Greenberg 2012-12-31 Sold Out 4.8%$82.4 - $94.02 $ 100.7116%0
Ronald Muhlenkamp 2012-12-31 Sold Out 1%$82.4 - $94.02 $ 100.7116%0
John Hussman 2012-12-31 Reduce -35.44%0.23%$82.4 - $94.02 $ 100.7116%184000
Joel Greenblatt 2012-12-31 Add 45.59%0.07%$82.4 - $94.02 $ 100.7116%42783
Ray Dalio 2012-12-31 Add 261.99%0.04%$82.4 - $94.02 $ 100.7116%58338
Scott Black 2012-12-31 Add 27.28%0.02%$82.4 - $94.02 $ 100.7116%8352
Mario Gabelli 2012-12-31 Add 33.33%$82.4 - $94.02 $ 100.7116%4000
John Hussman 2012-09-30 Reduce -43%0.37%$84.19 - $95.23 $ 100.7113%285000
Joel Greenblatt 2012-09-30 Add 40.93%0.05%$84.19 - $95.23 $ 100.7113%29385
Mario Gabelli 2012-09-30 New Buy$84.19 - $95.23 $ 100.7113%3000
Scott Black 2012-06-30 Reduce -22.3%0.03%$82.01 - $94.14 $ 100.7115%6897
Ray Dalio 2012-06-30 Reduce -64.68%0.03%$82.01 - $94.14 $ 100.7115%13516
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Laboratory Corporation of America Holdings

CEO of Laboratory Corp. of America Sold More than 80,000 Shares
July 11, 2012
On July 9, 2012, President & CEO of Laboratory Corp. of America Holdings (LH) David P King sold 84,800 shares of LH at an average price of $92.11. The total transaction amount is $7,810,928. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 17.30
LH's P/E(ttm) is ranked higher than
81% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.95 vs. LH: 17.30 )
LH' s 10-Year P/E(ttm) Range
Min: 12.54   Max: 57.29
Current: 17.3
12.54
57.29
P/B 3.40
LH's P/B is ranked lower than
52% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. LH: 3.40 )
LH' s 10-Year P/B Range
Min: 0.76   Max: 6.91
Current: 3.4
0.76
6.91
P/S 1.70
LH's P/S is ranked higher than
64% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. LH: 1.70 )
LH' s 10-Year P/S Range
Min: 0.3   Max: 3.25
Current: 1.7
0.3
3.25
PFCF 14.60
LH's PFCF is ranked higher than
74% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. LH: 14.60 )
LH' s 10-Year PFCF Range
Min: 3.79   Max: 32.9
Current: 14.6
3.79
32.9
EV-to-EBIT 11.5
LH's EV-to-EBIT is ranked higher than
87% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. LH: 11.5 )
LH' s 10-Year EV-to-EBIT Range
Min: 8.6   Max: 26
Current: 11.5
8.6
26
PEG 2.1
LH's PEG is ranked higher than
94% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. LH: 2.1 )
LH' s 10-Year PEG Range
Min: 0.75   Max: 26.38
Current: 2.1
0.75
26.38
Shiller P/E 19.2
LH's Shiller P/E is ranked higher than
100% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.19 vs. LH: 19.2 )
LH' s 10-Year Shiller P/E Range
Min: 16.09   Max: 59.21
Current: 19.2
16.09
59.21

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 16.7
LH's Price/Net Current Asset Value is ranked higher than
69% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. LH: 16.7 )
LH' s 10-Year Price/Net Current Asset Value Range
Min: 10.8   Max: 22.5
Current: 16.7
10.8
22.5
Price/DCF (Projected) 0.8
LH's Price/DCF (Projected) is ranked higher than
69% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. LH: 0.8 )
LH' s 10-Year Price/DCF (Projected) Range
Min: 0.7   Max: 1.9
Current: 0.8
0.7
1.9
Price/Median PS Value 0.9
LH's Price/Median PS Value is ranked higher than
69% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. LH: 0.9 )
LH' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.5
Current: 0.9
0.7
1.5
Price/Peter Lynch Fair Value 1.9
LH's Price/Peter Lynch Fair Value is ranked higher than
92% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. LH: 1.9 )
LH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 1.8
Current: 1.9
0.8
1.8
Earnings Yield (Greenblatt) 8.70
LH's Earnings Yield (Greenblatt) is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. LH: 8.70 )
LH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.8   Max: 11.6
Current: 8.7
3.8
11.6
Forward Rate of Return (Yacktman) 14.28
LH's Forward Rate of Return (Yacktman) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. LH: 14.28 )
LH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4   Max: 24.3
Current: 14.28
4
24.3

Business Description

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Since the Company's founding in 1971, it has grown into a national network of 54 primary laboratories and over 1,700 patient service centers along with a network of branches and STAT laboratories (which are laboratories that have the ability to perform certain routine tests quickly and report the results to the physician immediately). Through its national network of laboratories, the Company offers a broad range of clinical laboratory tests that are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease. In addition, the Company has developed testing operations, such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. Laboratory tests and procedures are used generally by hospitals, physicians and other health care providers and commercial clients to assist in the diagnosis, evaluation, detection, therapy selection, monitoring and treatment of diseases and other medical conditions through the examination of substances in the blood, tissues and other specimens. The Company believes that it competes favorably with its principal competitors in each of these areas and is currently implementing strategies designed to improve its competitive position. The Company's strategic plan continues to focus on three critical priorities: scientific differentiation, managed care, and customer service. The Company offers its services through a sales force focused on serving the specific needs of customers in different market segments. These market segments generally include Specialty Cancer, Hospitals and Primary Care. The Company is subject to licensing and regulation under federal, state and local laws and regulations relating to the protection of the environment and human health and safety and laws and regulations relating to the handling, transportation and disposal of medical specimens, infectious and hazardous waste and radioactive materials.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:ALR, DGX, LIFE, ENZ, IDXX
Traded in other countries:LAB.Germany
ยป More Articles for LH

Headlines

Articles On GuruFocus.com
My Top 10 Fairly Valued Fast-Growing Stocks May 14 2013 
Two Investment Ideas in Grey Owl Capital's Third Quarter Report Nov 02 2012 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
CEO of Laboratory Corp. of America Sold More than 80,000 Shares Jul 11 2012 
WEEKLY CFO SELLS HIGHLIGHT: AAPL, LH, WIFI, TWMC Apr 01 2012 
5 Healthcare Picks for 2012 Mar 21 2012 
Quest Diagnostics: A Strong 'Buy' Candidate in 2012 Mar 15 2012 
If I Had to Pick Growth Stocks... Mar 15 2012 
Quest in Position to Accelerate Growth Mar 11 2012 
Testing: Bio Reference Labs (BRLI), Quest Diagnostics Inc. (DGX), Laboratory Corp. of America (LH) - Mar 02 2012 

More From Our Partners
Cramer's Top Stock Picks: CLH SIX WFM May 23 2013 - THESTREET

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial